We are the world's first dedicated sickle cell news-magazine. We intend to teach, inform and help reduce the burden of sickle cell on family and society.
Social media
Lakiea Bailey, Ph.D
Sickle cell disease advocate, activist, research scientist...and occasionally...patient... with a doctorate in molecular hematology and regenerative medicine.
Social media
One 7-year-old who suffered his whole life from sickle cell disease now has a second chance thanks to his older sister's selfless donation.
Related story
A place where those living with Sickle Cell Anemia can come together and unite with others who are also go through the same. Here you will find support, love, education on Sickle Cell Anemia, and most of all a family!
Social media
Lillian E.C. McMahon, MD is an Associate Professor of Medicine at Boston University School of Medicine, Boston MA. Her research expertise and professional interests include sickle cell anemia, sickle cell disease, hemoglobin C disease, hemoglobinopathies.
Other Positions:
Associate Professor, Pediatric Subspecialties (Pediatric Hematology), Pediatrics, Boston University School of Medicine
Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center
Online profile
LaTonya Kittles Hendricks, a University of Maryland graduate with more than 20 years experience in health communications, heads PR Strategists. A vast majority of her experience has focused on public relations, health communications, and social marketing for federal agencies, including the National Institutes of Health.
LaTonya has led numerous communications programs focusing on:
-Public relations launches for scientific research initiatives
-Outreach to targeted populations, including scientists, physicians, and underserved communities
Online profile
Background:Sickle cell disease is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes. Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Stroke affects around 10% of children with sickle cell anaemia (HbSS). Chronic blood transfusions may reduce the risk of vaso-occlusion and stroke by diluting the proportion of sickled cells in the circulation. Objectives:To assess risks and benefits of chronic blood transfusion regimens in people with sickle cell disease for primary and secondary stroke prevention (excluding silent cerebral infarcts). Search methods:We searched for relevant trials in the Cochrane Library, MEDLINE (from 1946), Embase (from 1974), the Transfusion Evidence Library (from 1980), and ongoing trial databases; all searches current to 04 April 2016. Selection criteria:Randomised controlled trials comparing red blood cell transfusions as prophylaxis for stroke in people with sickle cell disease to alternative or standard treatment. There were no restrictions by outcomes examined, language or publication status. Data collection and analysis:Two authors independently assessed trial eligibility and the risk of bias and extracted data. Main results:We included five trials (660 participants) published between 1998 and 2016. Four of these trials were terminated early. The vast majority of participants had the haemoglobin (Hb)SS form of sickle cell disease. Three trials compared regular red cell transfusions to standard care in primary prevention of stroke: two in children with no previous long-term transfusions; and one in children and adolescents on long-term transfusion. Two trials compared the drug hydroxyurea (hydroxycarbamide) and phlebotomy to long-term transfusions and iron chelation therapy: one in primary prevention (children); and one in secondary prevention (children and adolescents).The quality of the evidence was very low to moderate across different outcomes according to GRADE methodology. This was due to the trials being at a high risk of bias due to lack of blinding, indirectness and imprecise outcome estimates.
Abstract sourceFull text
